Kura Oncology’s (KURA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Monday, Benzinga reports. They currently have a $32.00 price target on the stock.

Several other research firms have also recently issued reports on KURA. Wedbush reiterated an outperform rating and set a $37.00 target price on shares of Kura Oncology in a research report on Friday, August 9th. StockNews.com lowered Kura Oncology from a hold rating to a sell rating in a research note on Monday, April 15th. Cantor Fitzgerald reissued an overweight rating on shares of Kura Oncology in a research note on Friday, August 9th. JMP Securities reissued a market outperform rating and set a $32.00 price target on shares of Kura Oncology in a research note on Tuesday, June 18th. Finally, Stifel Nicolaus decreased their price target on Kura Oncology from $28.00 to $26.00 and set a buy rating on the stock in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $30.50.

Kura Oncology Stock Performance

NASDAQ KURA opened at $19.04 on Monday. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $20.60 and its two-hundred day moving average is $20.69. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -8.77 and a beta of 0.88.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same period last year, the firm posted ($0.53) EPS. The business’s revenue was up .0% on a year-over-year basis. Research analysts expect that Kura Oncology will post -2.56 EPS for the current year.

Insider Activity at Kura Oncology

In related news, insider Teresa Brophy Bair sold 2,615 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $22.15, for a total value of $57,922.25. Following the sale, the insider now owns 68,979 shares of the company’s stock, valued at approximately $1,527,884.85. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. DekaBank Deutsche Girozentrale lifted its stake in shares of Kura Oncology by 216.7% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 95,000 shares of the company’s stock worth $1,343,000 after purchasing an additional 65,000 shares during the period. BVF Inc. IL increased its holdings in shares of Kura Oncology by 9.5% during the 4th quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock worth $106,027,000 after buying an additional 642,245 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Kura Oncology during the 1st quarter worth $507,000. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Kura Oncology by 42.3% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 181,674 shares of the company’s stock worth $3,875,000 after buying an additional 54,031 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after buying an additional 28,212 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.